News for Trevi Therapeutics, Inc. (TRVI)

U.S. stocks were lower, with the Nasdaq Composite falling around 650 points on Monday. Shares of Redfin Corporation RDFN rose sharply during Monday's session a...

PR NewswireNEW HAVEN, Conn., Feb. 27, 2025 NEW HAVEN, Conn., Feb. 27, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopha

PR NewswireNEW HAVEN, Conn., Feb. 25, 2025 Topline results continue to be expected in the first half of 2025NEW HAVEN, Conn., Feb. 25, 2025 /PRNewswire/ --

Trevi Therapeutics (TRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PR NewswireNEW HAVEN, Conn., Dec. 16, 2024 NEW HAVEN, Conn., Dec. 16, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopha

Atai Life Sciences N.V. (ATAI) experienced a significant stock drop of 5.07%, with shares priced at $1.41 and a trading volume of 597,044 shares. The turnover r

Ginkgo Bioworks Holdings, Inc. (DNA) saw its stock price fall by 5.03%, currently trading at $10.16 per share with a trading volume of 485,937 shares and a turn

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 200 points on Thursday. The Dow traded down 0.46% to 43,947.18 whil...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling by 0.2% on Thursday. The Dow traded down 0.18% to 44,067.70 while the NASDAQ ...

Trevi (TRVI) stock shot up as much as 81% Thursday after the company said it won’t need to change the sample size for a Phase 2b study of its drug Haduvio. Read more here.

U.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling more than 50 points on Thursday. Following the market opening Thursday, the Dow...

California-based Palisade Bio, Inc. (PALI), a clinical-stage biopharmaceutical company is up over 110 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Trevi Therapeutics, Inc. (TRVI) Thursday reported positive outcome from sample size re-estimation for the ongoing Phase 2b CORAL trial in patients with idiopathic pulmonary fibrosis (IPF) who have chronic cough.

Read Equities Research Analysts’ Downgrades for May 18th (APO, APPF, AZN, BYCBF, CARR, CCBG, CENX, CF, CLH, CRH) at ETF Daily News